Dr. Christopher M. Iannuzzi
Claim this profileHartford HealthCare - Saint Vincent's Medical Center
Studies Prostate Adenocarcinoma
Studies Prostate Cancer
2 reported clinical trials
14 drugs studied
Affiliated Hospitals
Clinical Trials Christopher M. Iannuzzi is currently running
Hormone + Radiation Therapy
for Prostate Cancer
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
Recruiting2 awards Phase 36 criteria
Hormone Therapy + Radiation
for Prostate Cancer
This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts of the body. Decipher score in this study is used for patient selection and the two variations of treatment to be studied: intensification for higher Decipher score or de-intensification for low Decipher score. Patients with higher Decipher risk score will be assigned to the part of the study that compares the use of 6 months of the usual treatment (hormone therapy and radiation treatment) to the use of darolutamide plus the usual treatment (intensification). The purpose of this section of the study is to determine whether the additional drug can reduce the chance of cancer coming back and spreading in patients with higher Decipher score. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading. Alternatively, patients with low Decipher risk score will be assigned to the part of the study that compares the use of radiation treatment alone (de-intensification) to the usual approach (6 months of hormone therapy plus radiation). The purpose of this part of the study is to determine if radiation treatment alone is as effective compared to the usual treatment without affecting the chance of tumor coming back in patients with low Decipher score prostate cancer. Radiation therapy uses high energy to kill tumor cells and reduce the tumor size. Hormone therapy drugs such as darolutamide suppress or block the production or action of male hormones that play role in prostate cancer development. Effect of radiation treatment alone in patients with low Decipher score prostate cancer could be the same as the usual approach in stabilizing prostate cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy.
Recruiting2 awards Phase 31 criteria
More about Christopher M. Iannuzzi
Clinical Trial Related4 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Christopher M. Iannuzzi has experience with
- Bicalutamide
- Buserelin
- Degarelix
- Flutamide
- Goserelin
- Histrelin
Breakdown of trials Christopher M. Iannuzzi has run
Prostate Adenocarcinoma
Prostate Cancer
Stomach Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christopher M. Iannuzzi specialize in?
Christopher M. Iannuzzi focuses on Prostate Adenocarcinoma and Prostate Cancer. In particular, much of their work with Prostate Adenocarcinoma has involved treating patients, or patients who are undergoing treatment.
Is Christopher M. Iannuzzi currently recruiting for clinical trials?
Yes, Christopher M. Iannuzzi is currently recruiting for 2 clinical trials in Bridgeport Connecticut. If you're interested in participating, you should apply.
Are there any treatments that Christopher M. Iannuzzi has studied deeply?
Yes, Christopher M. Iannuzzi has studied treatments such as Bicalutamide, Buserelin, Degarelix.
What is the best way to schedule an appointment with Christopher M. Iannuzzi?
Apply for one of the trials that Christopher M. Iannuzzi is conducting.
What is the office address of Christopher M. Iannuzzi?
The office of Christopher M. Iannuzzi is located at: Hartford HealthCare - Saint Vincent's Medical Center, Bridgeport, Connecticut 06606 United States. This is the address for their practice at the Hartford HealthCare - Saint Vincent's Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.